AAV-2: how can the capsid be modified to improve the viral vector in gene therapy?

被引：0
|
作者：
Kreppel, Florian [1 ]
机构：
[1] Univ Ulm, Dept Gene Therapy, D-89081 Ulm, Germany
来源：
FUTURE VIROLOGY | 2010年 / 5卷 / 02期
关键词：
SEVERE COMBINED IMMUNODEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; LEBERS CONGENITAL AMAUROSIS; ADENOASSOCIATED VIRUS; IMMUNE-RESPONSE; SCID-X1; MUTATIONS; ADA;
D O I：
10.2217/FVL.10.6
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：133 / 135
页数：3
相关论文
共 50 条
  • [1] Antitumor activity of AAV-2 vector encoding modified TRAIL gene
    Yoo, JS
    Choi, SY
    Hwang, KS
    Cho, WK
    Jung, CR
    Im, DS
    MOLECULAR THERAPY, 2004, 9 : S364 - S364
  • [2] Tailoring the AAV vector capsid for gene therapy
    Vandenberghe, L. H.
    Wilson, J. M.
    Gao, G.
    GENE THERAPY, 2009, 16 (03) : 311 - 319
  • [3] Tailoring the AAV vector capsid for gene therapy
    L H Vandenberghe
    J M Wilson
    G Gao
    Gene Therapy, 2009, 16 : 311 - 319
  • [4] Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2
    D Grimm
    A Kern
    M Pawlita
    F K Ferrari
    R J Samulski
    J A Kleinschmidt
    Gene Therapy, 1999, 6 : 1322 - 1330
  • [5] Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2
    Grimm, D
    Kern, A
    Pawlita, M
    Ferrari, FK
    Samulski, RJ
    Kleinschmidt, JA
    GENE THERAPY, 1999, 6 (07) : 1322 - 1330
  • [6] The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
    Xie, Q
    Bu, WS
    Bhatia, S
    Hare, J
    Somasundaram, T
    Azzi, A
    Chapman, MS
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) : 10405 - 10410
  • [7] Gene therapy of Canavan disease:: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain
    Janson, C
    McPhee, S
    Bilaniuk, L
    Haselgrove, J
    Testaiuti, M
    Freese, A
    Wang, DJ
    Shera, D
    Hurh, P
    Rupin, J
    Saslow, E
    Goldfarb, O
    Goldberg, M
    Larijani, G
    Sharrar, W
    Liouterman, L
    Camp, A
    Kolodny, E
    Samulski, J
    Leone, P
    HUMAN GENE THERAPY, 2002, 13 (11) : 1391 - 1412
  • [8] Directed evolution of the AAV-2 capsid yields novel mutants
    Maheshri, N
    Schaffer, DV
    MOLECULAR THERAPY, 2003, 7 (05) : S347 - S348
  • [9] Duration of immunologically detectable AAV-2 capsid in an animal model
    Sabatino, DE
    Mingozzi, F
    Brooks, DC
    Schlachterman, A
    Edmonson, S
    Couto, L
    Colosi, P
    Chen, HF
    Ertl, HCJ
    High, KA
    MOLECULAR THERAPY, 2004, 9 : S16 - S16
  • [10] AAV-2 capsid-specific CD8+T cells limit the duration of gene therapy in humans and cross-react with AAV-8 capsid.
    Mingozzi, Federico
    Maus, Marcela V.
    Sabatino, Denise E.
    Hui, Daniel J.
    Rasko, John E. J.
    Ragni, Margaret V.
    Manno, Catherine Scott
    Ertl, Hildegund C. J.
    High, Katherine A.
    BLOOD, 2006, 108 (11) : 138A - 139A
12345